BMO Capital analyst Evan Seigerman lowered the firm’s price target on AbbVie (ABBV) to $208 from $228 and keeps an Outperform rating on ...

AbbVie said on Monday that an experimental schizophrenia drug it gained through an $8.7 billion deal for Cerevel Therapeutics failed two mid-stage studies, sending the drugmaker's shares plunging 12.5 ...

The global body contouring treatments market growth forecasted to transform from USD 1.46 billion in 2024 to USD 2.58 billion ...

Brianne Gardner, senior wealth manager at Velocity Investment Partners, Raymond James, discusses her past picks: WALMART, ...

GSK acquired an experimental therapy from Chimagen Biosciences, paying $300 million upfront for the “T-cell engager” therapy, ...

The foundation donation will go toward construction of UChicago Medicine's $815 million freestanding cancer care center in ...

Q3 2024 Earnings Call Transcript October 30, 2024 AbbVie Inc. beats earnings expectations. Reported EPS is $3, expectations ...

Macklem said the rate cuts are necessary because the Canadian economy is in a weaker state relative to the U.S. "The economy is growing but it's soft," he said. He added that the policy rate remains ...

This story first appeared in The Readout newsletter. Sign up for The Readout and receive STAT’s award-winning biotech news delivered straight to your inbox. Good morning. It’s a very ...

View upcoming earnings forecasts and in-depth analysis of company forecasts.

LATEST NEWS 05:00 How to pick the life insurance policy that’s right for you 05:00 Dublin AI start-up Glitch set to launch online ad platform 05:00 Movers & Shakers: MSD Ireland, Edelman, Ergo, Fáilte ...

This Ontario listing comes two months after Canada's Drug Agency (formerly CADTH) issued a reimbursement recommendation for VRAYLAR, and just days after AbbVie successfully reached an agreement ...